Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Immunex' Novantrone prostate cancer journal ads to begin in December.

Executive Summary

IMMUNEX NOVANTRONE PROSTATE CANCER JOURNAL ADS TO BEGIN IN DECEMBER following Nov. 13 supplemental approval of mitoxantrone injection for use in combination with corticosteroids as "initial chemotherapy for the treatment of patients with pain related to advanced hormone-refractory prostate cancer." FDA approved the additional oncologic indication one day before the application's (sNDA 19-297/S-014) Nov. 14 six-month user fee deadline.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS029173

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel